WEST PHARMACEUTICAL SERVICES (WST) Stock Fundamental Analysis

NYSE:WST • US9553061055

245.185 USD
+4.06 (+1.69%)
Last: Feb 23, 2026, 02:12 PM
Fundamental Rating

6

WST gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making WST a very profitable company, without any liquidiy or solvency issues. While showing a medium growth rate, WST is valued expensive at the moment. This makes WST very considerable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year WST was profitable.
  • WST had a positive operating cash flow in the past year.
  • WST had positive earnings in each of the past 5 years.
  • In the past 5 years WST always reported a positive cash flow from operatings.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • WST has a Return On Assets of 11.56%. This is amongst the best in the industry. WST outperforms 91.38% of its industry peers.
  • WST has a Return On Equity of 15.54%. This is amongst the best in the industry. WST outperforms 87.93% of its industry peers.
  • With an excellent Return On Invested Capital value of 13.83%, WST belongs to the best of the industry, outperforming 93.10% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for WST is above the industry average of 11.94%.
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROIC 13.83%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.69%
ROIC(5y)17.84%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • WST has a better Profit Margin (16.06%) than 86.21% of its industry peers.
  • In the last couple of years the Profit Margin of WST has remained more or less at the same level.
  • The Operating Margin of WST (20.16%) is better than 86.21% of its industry peers.
  • WST's Operating Margin has been stable in the last couple of years.
  • WST has a worse Gross Margin (35.91%) than 60.34% of its industry peers.
  • In the last couple of years the Gross Margin of WST has remained more or less at the same level.
Industry RankSector Rank
OM 20.16%
PM (TTM) 16.06%
GM 35.91%
OM growth 3Y-8.65%
OM growth 5Y0.48%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), WST is creating some value.
  • WST has less shares outstanding than it did 1 year ago.
  • WST has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, WST has an improved debt to assets ratio.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • WST has an Altman-Z score of 12.52. This indicates that WST is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 12.52, WST belongs to the top of the industry, outperforming 98.28% of the companies in the same industry.
  • The Debt to FCF ratio of WST is 0.43, which is an excellent value as it means it would take WST, only 0.43 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.43, WST belongs to the best of the industry, outperforming 91.38% of the companies in the same industry.
  • WST has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.06, WST is doing good in the industry, outperforming 63.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.43
Altman-Z 12.52
ROIC/WACC1.28
WACC10.81%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.02 indicates that WST has no problem at all paying its short term obligations.
  • The Current ratio of WST (3.02) is comparable to the rest of the industry.
  • A Quick Ratio of 2.34 indicates that WST has no problem at all paying its short term obligations.
  • The Quick ratio of WST (2.34) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.34
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

5

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 8.00% over the past year.
  • The Earnings Per Share has been growing by 8.94% on average over the past years. This is quite good.
  • Looking at the last year, WST shows a small growth in Revenue. The Revenue has grown by 6.25% in the last year.
  • Measured over the past years, WST shows a small growth in Revenue. The Revenue has been growing by 7.44% on average per year.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%

3.2 Future

  • WST is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.76% yearly.
  • Based on estimates for the next years, WST will show a small growth in Revenue. The Revenue will grow by 5.99% on average per year.
EPS Next Y7.67%
EPS Next 2Y10.28%
EPS Next 3Y10.83%
EPS Next 5Y10.76%
Revenue Next Year6.11%
Revenue Next 2Y6.14%
Revenue Next 3Y6.41%
Revenue Next 5Y5.99%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

3

4. Valuation

4.1 Price/Earnings Ratio

  • WST is valuated quite expensively with a Price/Earnings ratio of 33.63.
  • WST's Price/Earnings is on the same level as the industry average.
  • WST's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.99.
  • A Price/Forward Earnings ratio of 31.24 indicates a quite expensive valuation of WST.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of WST indicates a somewhat cheap valuation: WST is cheaper than 60.34% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.02, WST is valued at the same level.
Industry RankSector Rank
PE 33.63
Fwd PE 31.24
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, WST is valued a bit cheaper than 67.24% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, WST is valued a bit cheaper than the industry average as 65.52% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 37.62
EV/EBITDA 21.18
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates WST does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of WST may justify a higher PE ratio.
PEG (NY)4.38
PEG (5Y)3.76
EPS Next 2Y10.28%
EPS Next 3Y10.83%

6

5. Dividend

5.1 Amount

  • WST has a yearly dividend return of 0.32%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.10, WST pays a better dividend. On top of this WST pays more dividend than 84.48% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, WST's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.32%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.48%.
  • WST has been paying a dividend for at least 10 years, so it has a reliable track record.
  • WST has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)5.48%
Div Incr Years32
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • WST pays out 12.40% of its income as dividend. This is a sustainable payout ratio.
  • WST's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP12.4%
EPS Next 2Y10.28%
EPS Next 3Y10.83%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

WEST PHARMACEUTICAL SERVICES

NYSE:WST (2/23/2026, 2:12:09 PM)

245.185

+4.06 (+1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-22
Inst Owners97.92%
Inst Owner Change-2.12%
Ins Owners0.33%
Ins Owner Change0.37%
Market Cap17.64B
Revenue(TTM)3.07B
Net Income(TTM)493.70M
Analysts80.87
Price Target353.41 (44.14%)
Short Float %3.58%
Short Ratio2.69
Dividend
Industry RankSector Rank
Dividend Yield 0.32%
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP12.4%
Div Incr Years32
Div Non Decr Years34
Ex-Date01-28
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)10.24%
Max EPS beat(2)15.4%
EPS beat(4)4
Avg EPS beat(4)15.68%
Min EPS beat(4)10.24%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)12.16%
EPS beat(12)11
Avg EPS beat(12)11.7%
EPS beat(16)14
Avg EPS beat(16)11.27%
Revenue beat(2)2
Avg Revenue beat(2)0.72%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.1%
Revenue beat(4)4
Avg Revenue beat(4)1.63%
Min Revenue beat(4)0.33%
Max Revenue beat(4)4.33%
Revenue beat(8)7
Avg Revenue beat(8)1.11%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.34%
PT rev (1m)-0.18%
PT rev (3m)-0.06%
EPS NQ rev (1m)1.83%
EPS NQ rev (3m)2.04%
EPS NY rev (1m)0%
EPS NY rev (3m)1.03%
Revenue NQ rev (1m)2.39%
Revenue NQ rev (3m)2.47%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 33.63
Fwd PE 31.24
P/S 5.74
P/FCF 37.62
P/OCF 23.37
P/B 5.55
P/tB 5.77
EV/EBITDA 21.18
EPS(TTM)7.29
EY2.97%
EPS(NY)7.85
Fwd EY3.2%
FCF(TTM)6.52
FCFY2.66%
OCF(TTM)10.49
OCFY4.28%
SpS42.73
BVpS44.15
TBVpS42.51
PEG (NY)4.38
PEG (5Y)3.76
Graham Number85.1
Profitability
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROCE 17.14%
ROIC 13.83%
ROICexc 17.71%
ROICexgc 18.48%
OM 20.16%
PM (TTM) 16.06%
GM 35.91%
FCFM 15.25%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.69%
ROIC(5y)17.84%
ROICexc(3y)20.15%
ROICexc(5y)23.86%
ROICexgc(3y)21.15%
ROICexgc(5y)25.26%
ROCE(3y)19.45%
ROCE(5y)22.11%
ROICexgc growth 3Y-14.58%
ROICexgc growth 5Y-3.63%
ROICexc growth 3Y-14.12%
ROICexc growth 5Y-2.75%
OM growth 3Y-8.65%
OM growth 5Y0.48%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.43
Debt/EBITDA 0.26
Cap/Depr 166.8%
Cap/Sales 9.3%
Interest Coverage 2065.67
Cash Conversion 95.41%
Profit Quality 94.98%
Current Ratio 3.02
Quick Ratio 2.34
Altman-Z 12.52
F-Score7
WACC10.81%
ROIC/WACC1.28
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y7.67%
EPS Next 2Y10.28%
EPS Next 3Y10.83%
EPS Next 5Y10.76%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
Revenue Next Year6.11%
Revenue Next 2Y6.14%
Revenue Next 3Y6.41%
Revenue Next 5Y5.99%
EBIT growth 1Y5.95%
EBIT growth 3Y-6.72%
EBIT growth 5Y7.96%
EBIT Next Year40.02%
EBIT Next 3Y19.6%
EBIT Next 5Y14.44%
FCF growth 1Y69.65%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y15.52%
OCF growth 3Y1.4%
OCF growth 5Y9.82%

WEST PHARMACEUTICAL SERVICES / WST FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 6 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.


Can you provide the profitability details for WEST PHARMACEUTICAL SERVICES?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 7 / 10.


Can you provide the financial health for WST stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.


How sustainable is the dividend of WEST PHARMACEUTICAL SERVICES (WST) stock?

The dividend rating of WEST PHARMACEUTICAL SERVICES (WST) is 6 / 10 and the dividend payout ratio is 12.4%.